CAS 2342583-66-6

Formula: C22H28F3N7

InChI: InChI=1S/C22H28F3N7/c1-14(16-7-8-16)32-13-28-18-19(29-21(30-20(18)32)26-9-10-31(2)3)27-12-15-5-4-6-17(11-15)22(23,24)25/h4-6,11,13-14,16H,7-10,12H2,1-3H3,(H2,26,27,29,30)

InChI key: GHRNSZVMIARHIS-UHFFFAOYSA-N

SMILES: CC(C1CC1)N2C=NC3=C(N=C(N=C32)NCCN(C)C)NCC4=CC(=CC=C4)C(F)(F)F

NCC007

CAS: 2342583-66-6

Formula: C₂₂H₂₈F₃N₇

Purity: 98%

Molecular weight: 447.4998

Ref: IN-DA01KKFG

NCC007

CAS: 2342583-66-6

NCC007

Formula: C₂₂H₂₈F₃N₇

Purity: ≥98%

Molecular weight: 447.5

Ref: 54-BUP10430

NCC007

CAS: 2342583-66-6

NCC007 is a novel CKIα and CKIδ dual inhibitors by structural modification of N9 and C2 position of longdaysin.

Formula: C₂₂H₂₈F₃N₇

Purity: 98.88%

Color and Shape: Solid

Molecular weight: 447.5

Ref: TM-T7949

NCC007

CAS: 2342583-66-6

NCC007 is a drug that inhibits casein kinase. Casein kinase is involved in cell proliferation and differentiation. NCC007 is being studied for its potential use as an anticancer therapeutic. Inhibition of casein kinase leads to the phosphorylation of casein, which may inhibit tumor growth by disrupting the circadian rhythm. NCC007 has been shown to be effective against cancer cells grown in vitro and in vivo. This drug also has the ability to modulate cellular pathways, such as endogenous protein synthesis, cellular signaling, and cell cycle progression. Optimization of cancer drugs has been shown using x-ray crystal structures of the human protein Csk-1 (casein kinase).

Formula: C₂₂H₂₈F₃N₇

Purity: Min. 95%

Molecular weight: 447.5 g/mol

Ref: 3D-STD58366